


BD solutions for enabling delivery of complex biologics

# BD Libertas™ Wearable Injector



## BD Libertas™ design features

- Single use, fixed dose, glass syringe barrel primary container
- Dose delivery options: 2-5 mL or 5-10 mL
- Mechanical spring-based power module
- Transparent viewing window for drug and drug delivery visibility
- Color-coded status indicator
- Push button activation
- Pre-attached adhesive pad

## Experience

- BD conducted a **52-subject human clinical trial** with the BD Libertas™ Wearable Injector that evaluated the **performance of the 5 mL device**, including tissue effects, tolerance (pain) and **patient acceptance**<sup>2</sup> > **100% of study subjects** likely to use if prescribed<sup>2</sup>
- BD has performed multiple market research, generative and formative user studies to inform the design of the BD Libertas™ Wearable Injector


## Availability

- Container and device samples available upon request

## Key benefits

BD Libertas™ Wearable Injector is designed to deliver subcutaneous injections of **large volume (2-5 mL or 5-10 mL) and/or high viscosity (up to 50 cP)** fixed dose biologics for the non-acute setting:<sup>1</sup>

- Designed to be prefilled and ready to use; no patient assembly required<sup>1</sup>
- Enables hands-free drug delivery<sup>1</sup>
- Features automated needle insertion and passive\* needle retraction<sup>1</sup>
- Provides multiple indications of injection status (audible, tactile, visual) throughout the injection process<sup>1,2</sup>



BD Libertas™ Wearable Injector is a product in development; some statements are forward looking and are subject to a variety of risks and uncertainties. BD Libertas™ Wearable Injector is a device component intended for drug-device combination products and not subject to FDA 510(k) clearance or separate EU CE mark certification.

#### References

- † Designed to inject or infuse the drug therapy hands-free once activated
- \* Needle retracts automatically upon injection completion without additional user steps
- 1 Design Input Specification for BD Libertas™ Platform [Internal report]. Franklin Lakes, USA: Becton Dickinson and Company; 2021
- 2 Wendy D Woodley, Wen Yue, Didier R Morel, Audrey Lainesse, Ronald J Pettis, & Natasha G Bolick (2020) Clinical Evaluation of an Investigational 5ml Wearable Injector in Healthy Human Subjects, Clinical and Translational Science, DOI: 10.1111/cts.12946

#### **BD Medical**

Pharmaceutical Systems

#### **United States**

1 Becton Drive  
Franklin Lakes, NJ 07417  
+1 800 225 3310

#### **Europe**

11 rue Aristide-Bergès  
38800 Le Pont-de-Claix  
France

Phone: +33 4 76 68 36 36 - Fax: +33 4 76 68 35 05

Becton Dickinson France S.A.S - Share capital: 64 719 915 €  
RCS Grenoble B 056 501 711

**bd.com**

